Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40161 | ISIN: US74275C3043 | Ticker-Symbol:
NASDAQ
02.07.25 | 21:59
0,188 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
PROCESSA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
PROCESSA PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur PROCESSA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiProcessa hands cancer candidate back to Opus Genetics after deciding milestone out of reach3
PROCESSA PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoProcessa Pharmaceuticals, Inc. - 8-K, Current Report2
MoProcessa Pharmaceuticals: Kursziel von H.C. Wainwright auf 2 US-Dollar gesenkt1
MoProcessa Pharmaceuticals price target lowered to $2 at H.C. Wainwright2
17.06.Processa Pharmaceuticals, Inc. - 8-K, Current Report1
17.06.Processa inks licensing deal with Intact for gastroparesis drug2
17.06.Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate199$452.5 million in total milestone payments$2.5 million in near-term paymentsDouble-digit royalties on future net product sales3.5% equity stake in Intact Therapeutics HANOVER, Md., June 17, 2025 (GLOBE...
► Artikel lesen
13.06.Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 20252
13.06.Processa Pharmaceuticals, Inc. - S-1, General form for registration of securities2
30.05.Processa Pharmaceuticals presents cancer drug advances at ASCO3
30.05.Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting1
08.05.Processa Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
20.03.Processa Pharmaceuticals, Inc. - 10-K, Annual Report1
21.02.Processa Pharmaceuticals, Inc. (PCSA): Among the Cheapest Stocks Insiders Are Buying Recently2
10.02.Processa Pharmaceuticals, Inc. - 8-K, Current Report-
30.01.Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules1
30.01.Processa Pharmaceuticals, Inc. - 8-K, Current Report1
28.01.Processa Pharmaceuticals prices $5M equity offering2
28.01.Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules2
27.01.Processa Pharmaceuticals, Inc. - S-1/A, General form for registration of securities-
Weiter >>
22 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1